Detalhe da pesquisa
1.
Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer.
Int J Mol Sci
; 22(23)2021 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34884893
2.
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
Oncogene
; 43(4): 265-280, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030789
3.
ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
Cancer Discov
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591846
4.
ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
bioRxiv
; 2023 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37961351
5.
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Cancer Cell
; 41(8): 1427-1449.e12, 2023 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37478850
6.
Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
Crit Rev Oncog
; 27(1): 81-96, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35993980
7.
The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
Clin Transl Med
; 12(2): e695, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184376
8.
Targeting radioresistance and replication fork stability in prostate cancer.
JCI Insight
; 7(9)2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35349486
9.
Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
JCI Insight
; 7(17)2022 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35881485
10.
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
Sci Transl Med
; 12(559)2020 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32878980
11.
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer.
Oncotarget
; 9(18): 14268-14284, 2018 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29581842